FDA Approved: ENVARSUS XR — Supplemental Application (Veloxis Pharmaceuticals, Inc)

View source ↗

Summary

FDA processed a supplemental approval for ENVARSUS XR (tacrolimus) from Veloxis Pharmaceuticals, potentially expanding its labeling or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplant Rejection
• Kidney Transplant Rejection
• Liver Transplant Rejection

Drugs mentioned

• Envarsus XR (Tacrolimus)

Snippet

SUPPL AP for ENVARSUS XR (TACROLIMUS)